On November 5, 2015 Kite Pharma, Inc. (Kite) (Nasdaq:KITE) reported upcoming presentations related to KTE-C19, Kite’s lead product candidate, that will take place at the 57th ASH (Free ASH Whitepaper) Annual Meeting in Orlando, Florida, December 5-8, 2015 (Press release, Kite Pharma, NOV 5, 2015, View Source [SID:1234507983]). KTE-C19 is an investigational therapy in which a patient’s T cells are genetically engineered to express a chimeric antigen receptor (CAR) designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. Kite recently announced that the ZUMA-1 trial transitioned to the pivotal Phase 2 trial.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are encouraged by the preliminary findings seen in Phase 1 of our first company-sponsored trial and look forward to presenting the data in a peer-reviewed setting," said Dr. Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer of Kite. "Additional biomarker data to be presented will further the understanding of pharmacodynamic mechanisms of KTE-C19 and the importance of optimizing the conditioning chemotherapy regimen prior to KTE-C19 therapy."
The accepted abstracts are listed below and are now available online on the ASH (Free ASH Whitepaper) conference website: View Source
2015 ASH (Free ASH Whitepaper) Annual Meeting Presentations
Title: Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy
Date: Saturday, December 5, 2015: 5:30 – 7:30 PM Eastern
Session: 801. Gene Therapy and Transfer: Poster I
Abstract number: 2042
Location: Orange County Convention Center, Hall A
Presenter: Adrian Bot, M.D., Ph.D., Kite Pharma, Santa Monica, CA
Title: Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Date: Sunday, December 6, 2015: 6:00 – 8:00 PM Eastern
Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II
Abstract number: 2730
Location: Orange County Convention Center, Hall A
Presenter: Sattya S. Neelapu, M.D., The University of Texas MD Anderson Cancer Center, Houston, TX
Title: Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Date: Monday, December 7, 2015: 6:00 – 8:00 PM Eastern
Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III
Abstract number: 3991
Location: Orange County Convention Center, Hall A
Presenter: Frederick L. Locke, M.D., Moffitt Cancer Center, Tampa, FL
Title: Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy
Date: Monday, December 7, 2015: 6:00 – 8:00 PM Eastern
Session: 801. Gene Therapy and Transfer: Poster III
Abstract number: 4426
Location: Orange County Convention Center, Hall A
Presenter: Adrian Bot, M.D., Ph.D., Kite Pharma, Santa Monica, CA